Extrarenal monoclonal immunoglobulin deposition disease: mechanisms, clinical presentation, diagnostics and treatment approaches (review)
https://doi.org/10.24884/1609-2201-2024-103-3-31-40
Abstract
In monoclonal gammopathies the aberrant B-cell clone produces the monoclonal immunoglobulin (MIG) which could present as only one light chain or only one heavy chain or the whole immunoglobulin. Due to somatic mutations in B-cell clone genetic the MIG obtains abnormal features and different types of tissue toxicity. The condition of non-organized granular MIG deposition leading to organ damage and dysfunction is known as monoclonal immunoglobulin deposition disease (MIDD). Most commonly MIDD involves the kidney parenchyma. However, extrarenal MIDD may affect other tissues and present as local or systemic condition. This review summarizes the current knowledge concerning the mechanisms, clinical manifestation, diagnostics and treatment approaches in extrarenal MIDD.
About the Author
M. S. Khrabrova
Pavlov University
Russian Federation
Russian Federation
Maria S. Khrabrova, Cand of Sci. (Med.), Associate Professor of the Pavlov University, Department of Propaedeutic of Internal Diseases, Associate Professor of the Department of Propaedeutics of Internal Diseases with clinic named after acad. M. D. Tushinksy
6–8, L’va Tolstogo str., Saint Petersburg, 197022
References
1. Multiple myeloma – Aquick refl ction on the fast progress / eds by Hajek R. InTech, 2013. 236 p. http://dx.doi.org/10.5772/56515.
2. Del Pozo-Yauner L., Herrera G. A., Perez Carreon J. I. et al. Role of the mechanisms for antibody repertoire diversification in monoclonal light chain deposition disorders: when a friend becomes foe. Front Immunol. 2023;14:1203425. https://doi.org/10.3389/fimmu.2023.1203425.
3. Dispenzieri A. Monoclonal gammopathies of clinical signifi ance. Hematology Am Soc Hematol Educ Program. 2020;2020(1):380– 388. https://doi.org/10.1182/hematology.2020000122.
4. Fermand J. P., Bridoux F., Dispenzieri A. et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478–1485. https://doi.org/10.1182/blood-2018-04-839480.
5. Leung N., Bridoux F., Nasr S. H. Monoclonal gammopathy of renal significance. N Engl J Med. 2021;384(20):1931–1941. https://doi.org/10.1056/NEJMra1810907.
6. Smirnov A. V., Afanasyev B. V., Poddubnaya I. V. et al. Monoclonal gammopathy of renal significance: Consensus of hematologists and nephrologists of Russia on the establishment of nosology, diagnostic approach and rationale for clone specific treatment. Nephrology. 2019;23(6):9–28. https://doi.org/10.36485/15616274-2019-236-9-28. (In Russ.).
7. Khrabrova M. S., Dobronravov V. A., Smirnov A. V. Kidney disease associated with monoclonal gammopathies: Single-center study. Nephrology. 2018;22(6):38–46. (In Russ.). https://doi.org/10.24884/1561-6274-2018-22-6-38-46.
8. Cohen C., Joly F., Sibille A. et al. Randall-type monoclonal immunoglobulin deposition disease: New insights into the pathogenesis, diagnosis and management. Diagnostics (Basel). 2021;11(3):420. https://doi.org/10.3390/diagnostics11030420.
9. Herrera G. A., Teng J., Turbat-Herrera E. A. et al. Understanding mesangial pathobiology in AL-Amyloidosis and monoclonal ig light chain deposition disease. Kidney Int Rep. 2020;5(11):1870– 1893. https://doi.org/10.1016/j.ekir.2020.07.013.
10. Joly F., Cohen C., Javaugue V. et al. Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. Blood. 2019;133(6):576–587. https://doi.org/10.1182/blood-2018-09-872028.
11. Pozzi C., Locatelli F. Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol. 2002;22(4):319–30.
12. Pozzi C., D’Amico M., Fogazzi G. B. et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154–63. https://doi.org/10.1053/j.ajkd.2003.08.040.
13. Ikura H., Endo J., Kitakata H. et al. Molecular mechanism of pathogenesis and treatment strategies for AL amyloidosis. Int J Mol Sci. 2022;23(11):6336. https://doi.org/10.3390/ijms23116336.
14. Weichman K., Dember L. M., Prokaeva T. et al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with highdose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006;38(5):339–43. https://doi.org/10.1038/sj.bmt.1705447.
15. Vidal R., Goñi F., Stevens F. et al. Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition. Am J Pathol. 1999;155(6):2009–17. https://doi.org/10.1016/s00029440(10)65520-4.
16. Tsushima T., Suzuki T., Terao T. et al. Light chain deposition disease involving kidney and liver in a patient with IgD myeloma. BMC Nephrol. 2021;22(1):40. https://doi.org/10.1186/s12882-021-02246-9.
17. Nishioka R., Yoshida S., Takamatsu H., Kawano M. Cardiac light-chain deposition disease and hints at diagnosing: a case report. Eur Heart J Case Rep. 2023;7(2):ytad049. https://doi.org/10.1093/ehjcr/ytad049.
18. Palladini G., Dispenzieri A., Gertz M. A. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–9. https://doi.org/10.1200/JCO.2011.37.7614.
19. Said S. M., Best Rocha A., Valeri A. M. et al. The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. Kidney Int. 2022;101(1):152–163. https://doi.org/10.1016/j.kint.2021.10.019.
20. Gudkova A. Y., Lapekin S. V., Bezhanishvili T. G. et al. AL-amyloidosis with cardiac involvement. Diagnostic capabilities of non-invasive methods. Terapevticheskii arkhiv. 2021;93(4):487–496. https://doi.org/10.26442/00403660.2021.04.200689. (In Russ.).
21. Ramonatxo A., Garcia R., Joly F. et al. Randall-type monoclonal immunoglobulin deposition disease: description of cardiac involvement. European Heart Journal. 2020;41(2):ehaa946.2140. https://doi.org/10.1093/ehjci/ehaa946.2140.
22. Buxbaum J. N., Genega E. M., Lazowski P. et al. Infiltrative nonamyloidotic monoclonal immunoglobulin light chain cardiomyopathy: an underappreciated manifestation of plasma cell dyscrasias. Cardiology. 2000;93(4):220–8. https://doi.org/10.1159/000007030.
23. Mohan M., Buros A., Mathur P. et al. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017;92(8):739–745. https://doi.org/10.1002/ajh.24756.
24. Gandhi M., Pasha S. B., Reznicek E. et al. A case of light chain deposition disease leading to acute liver failure and review of literature. Diseases. 2023;11(1):24. https://doi.org/10.3390/diseases11010024.
25. Grembiale A., Garlatti E., Ermacora A. et al. An unusual case of cholestatic hepatitis due to light-chain deposition disease. Case Rep Oncol. 2020;13(3):1343–1348. https://doi.org/10.1159/000509508.
26. Brilland B., Sayegh J., Croue A. et al. Recovery from LCDD-associated Severe Liver Cholestasis: a case report and literature review. J Gastrointestin Liver Dis. 2016;25(1):99–103. https://doi.org/10.15403/jgld.2014.1121.251.lcd.
27. Gonçalves T. A. P., Donadel C. D., Frezatti R. S. S. et al. Monoclonal gammopathy-associated peripheral neuropathies: Uncovering pearls and challenges. J Peripher Nerv Syst. 2024,29(2):161‒172. https://doi.org/10.1111/jns.12638.
28. Lunn M. P. Neuropathies and paraproteins. Curr Opin Neurol. 2019;32(5):658–665. https://doi.org/10.1097/WCO.0000000000000726.
29. Chompoopong P., Mauermann M. L., Siddiqi H., Peltier A. Amyloid neuropathy: From pathophysiology to treatment in lightchain amyloidosis and hereditary transthyretin amyloidosis. Ann Neurol. 2024;96(3):423–440. https://doi.org/10.1002/ana.26965.
30. Grassi M. P., Clerici F., Perin C. et al. Light chain deposition disease neuropathy resembling amyloid neuropathy in a multiple myeloma patient. Ital J Neurol Sci. 1998;19(4):229–33. https://doi.org/10.1007/BF02427609.
31. Romano A., Riso V., Bisogni G. et al. Isolated light chain deposition disease neuropathy in a patient with multiple myeloma. Amyloid. 2020;27(1):67–68. https://doi.org/10.1080/13506129.2019.1669554.
32. Foguem C., Manckoundia P., Pfi P., Dupond J. L. Peripheral neuropathy and VIth nerve palsy related to randall disease successfully treated by high-dose melphalan, autologous blood stem cell transplantation, and VIth nerve decompression surgery. Case Rep Med. 2010;2010:542925. https://doi.org/10.1155/2010/542925.
33. Luigetti M., Frisullo G., Laurenti L. et al. Light chain deposition in peripheral nerve as a cause of mononeuritis multiplex in Waldenström’s macroglobulinaemia. J Neurol Sci. 2010;291(1– 2):89–91. https://doi.org/10.1016/j.jns.2010.01.018.
34. Popović M., Tavćar R., Glavac D. et al. Light chain deposition disease restricted to the brain: The fi case report. Hum Pathol. 2007;38(1):179–84. https://doi.org/10.1016/j.humpath.2006.07.010.
35. Mercado J. J., Markert J. M., Meador W. et al. Primary CNS nonamyloidogenic light chain deposition disease: case report and brief review. Int J Surg Pathol. 2017;25(8):755–760. https://doi.org/10.1177/1066896917717338.
36. Singh A., Okonkwo L., Hoffmann J. C. et al. Nonamyloid tumoral light-chain-deposition disease (aggregoma) of the paraspinal region. Skeletal Radiol. 2015;44(12):1839–43. https://doi.org/10.1007/s00256-015-2223-4.
37. Matjašič A., Wechtersbach K., Kavalar R. et al. Brain aggregoma with clonal B-cell perivascular proliferation detected by next-generation sequencing. A case report and review of the literature. Folia Neuropathol. 2021;59(2):205–211. https://doi.org/10.5114/fn.2021.106405.
38. Skardelly M., Pantazis G., Bisdas S. et al. Primary cerebral lowgrade B-cell lymphoma, monoclonal immunoglobulin deposition disease, cerebral light chain deposition disease and “aggregoma”: an update on classification and diagnosis. BMC Neurol. 2013;13:107. https://doi.org/10.1186/1471-2377-13-107.
39. Wei C., Wang M., Li J. et al. Light chain deposition disease presenting with gastrointestinal disorder as primary manifestation: report of two cases and literature review. J Int Med Res. 2024;52(3):3000605241233972. https://doi.org/10.1177/03000605241233972.
40. Lestelle F., Beigelman C., Rotzinger D. et al. Phenotypes and outcome of diffuse pulmonary non-amyloid light chain deposition disease. Respir Res. 2024;25(1):159. https://doi.org/10.1186/s12931-024-02798-y.
41. Baqir M., Moua T., White D. et al. Pulmonary nodular and cystic light chain deposition disease: A retrospective review of 10 cases. Respir Med. 2020;164:105896. https://doi.org/10.1016/j.rmed.2020.105896.
42. KhoorA., Myers J. L., Tazelaar H. D., Kurtin P. J.Amyloid-like pulmonary nodules, including localized light-chain deposition: clinicopathologic analysis of three cases. Am J Clin Pathol. 2004;121(2):200–4. https://doi.org/10.1309/3GEC-PW24-02F6-V8EK.
43. Bhargava P., Rushin J. M., Rusnock E. J. et al. Pulmonary light chain deposition disease: report of five cases and review of the literature. Am J Surg Pathol. 2007;31(2):267–76. https://doi.org/10.1097/01.pas.0000213358.18380.d2.
44. Colombat M., Holifanjaniaina S., Guillonneau F. et al. Mass spectrometry-based proteomic analysis: a good diagnostic tool for cystic lung light chain deposition disease. Am J Respir Crit Care Med. 2013;188(3):404–5. https://doi.org/10.1164/rccm.201301-0071LE.
45. Colombat M., Mal H., Copie-Bergman C. et al. Primary cystic lung light chain deposition disease: a clinicopathologic entity derived from unmutated B cells with a stereotyped IGHV434/IGKV1 receptor. Blood. 2008;112(5):2004–12. https://doi.org/10.1182/blood-2007-11-123596.
46. Rajapreyar I., Joly J., Tallaj J. et al. Pulmonary vascular disease due to plasma cell dyscrasia. Mayo Clin Proc Innov Qual Outcomes. 2020;5(1):210–218. https://doi.org/10.1016/j.mayocpiqo.2020.09.004.
47. Claveau J. S., Wetter D. A., Kumar S. Cutaneous manifestations of monoclonal gammopathy. Blood Cancer J. 2022;12(4):58. https://doi.org/10.1038/s41408-022-00661-1.
48. Alegría-Landa V., Cerroni L., Kutzner H., Requena L. Paraprotein deposits in the skin. J Am Acad Dermatol. 2017;77(6):1145–1158. https://doi.org/10.1016/j.jaad.2017.07.039.
49. Topalidis C., Boulogeorgou K., Lazaridis A., Koletsa T. Light chain deposition disease: spotlight on a rare cutaneous disease. Eur J Dermatol. 2023;33(3):297–299. https://doi.org/10.1684/ejd.2023.4486.
50. Safa G., Dhib M., Soubrane J. C. et al. Maladie des dépôts de chaînes lourdes et légères avec manifestations cutanées et rénales [Light and heavy chain deposition disease with cutaneous and renal manifestations]. Ann Dermatol Venereol. 1996;123(8):490–2. (In French).
51. Hendricks C., Fernández Figueras M. T., Liersch J. et al. Cutaneous light chain deposition disease: A report of 2 cases and review of the literature. Am J Dermatopathol. 2018;40(5):337–341. https://doi.org/10.1097/DAD.000000000000099.
52. O’Malley J. T., D’Agati V. D., Sherman W. H., Grossman M. E. Acquired cutis laxa associated with heavy chain deposition disease involving dermal elastic fi JAMA Dermatol. 2014;150(11):1192–6. https://doi.org/10.1001/jamadermatol.2014.725.
53. Dima D., Jiang D., Singh D. J. et al. Multiple myeloma therapy: Emerging trends and challenges. Cancers (Basel). 2022;14(17):4082. https://doi.org/10.3390/cancers14174082.
54. Aimo A., Vergaro G., Pucci A. et al. Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid. 2017;24(2):135–137. https://doi.org/10.1080/13506129.2017.1334196.
Review
For citations:
Khrabrova M.S. Extrarenal monoclonal immunoglobulin deposition disease: mechanisms, clinical presentation, diagnostics and treatment approaches (review). New St. Petersburg Medical Records. 2024;(3):31-40. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-3-31-40
Views:
53
Email this article 